New dose schedule for J&J bispecific; Layoffs at Ring Therapeutics; Regeneron’s priority review

21 Feb 2024

Priority ReviewDrug ApprovalPhase 3Accelerated Approval

Plus, news about Enveric Biosciences and Kazia Therapeutics: Johnson & Johnson’s bispecific gets a new dosing schedule: The FDA approved a reduced dosing regimen for J&J’s multiple myeloma bispecific antibody Tecvayli, the pharma company announced Tuesday evening. The reduced dosing approval comes as the drug’s side effects, such as cytokine release syndrome and serious infections, are substantial . The treatment is approved for multiple myeloma patients who have received four prior lines of therapy, but now those who have been in remission for at least six months can move down from a weekly to a biweekly dosing schedule. — Lei Lei Wu

For more details,please visit the original website

The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.

Organizations

Ring Therapeutics, Inc.

Regeneron Pharmaceuticals, Inc.

Enveric Biosciences, Inc.

[+2]

Indications

Multiple MyelomaCytokine Release SyndromeInfectious Diseases

Targets

Drugs

Teclistamab

Chat with Hiro

Hot reports

GPRC5D Target Patent Research Report

Patsnap Synapse

Global Drug R&D Express (July 2024)

PatSnap Synapse

siRNA Drug Amvuttra Patent Research and Practical Operation Guide

Patsnap Synapse

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.